EBITDA CAGR uses clean operating EBITDA derived from reported operating income plus depreciation and amortization.
Over longer horizons, EBITDA CAGR averages 70.87% over 3 years; the trailing 12 months came in at +189.27%. EBITDA CAGR shows how the company's operating profitability has grown before depreciation and amortization. This reflects the growth of the core business's cash-operating earnings power, independent of capital-intensity and accounting depreciation choices.
Anbio Biotechnology Class A Ordinary Shares (NNNN)
Reported quarterly EBITDA; no daily interpolation. Q4 FY2025 (2025-12-31): $2.80M.
| Year | Start EBITDA | End EBITDA | Change | % Change |
|---|---|---|---|---|
| 2025 | $2.00M | $5.77M | +$3.77M | +189.06% |
| 2024 | $1.97M | $2.00M | +$21.40K | +1.08% |
| 2023 | $10.20M | $1.97M | −$8.23M | -80.65% |
| 2022 | $2.46M | $10.20M | +$7.75M | +315.40% |
| Period | Period End | Value | QoQ Growth | YoY Growth |
|---|---|---|---|---|
| Q4 FY2025 | 2025-12-31 | $2.80M | N/A | N/A |
| Q2 FY2025 | 2025-06-30 | $3.68M | N/A | N/A |
| Q4 FY2024 | 2024-12-31 | -$1.74M | N/A | N/A |
| Q2 FY2024 | 2024-06-30 | $3.89M | N/A | N/A |
| Q4 FY2023 | 2023-12-31 | $587,280 | N/A | N/A |
| Q2 FY2023 | 2023-06-30 | $1.55M | N/A |
| N/A |
QoQ Growth compares the previous fiscal quarter; YoY Growth compares the same fiscal quarter in the prior fiscal year. Missing or ambiguous fiscal periods render N/A.
